178 related articles for article (PubMed ID: 11895925)
1. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Chan DC; Earle KA; Zhao TL; Helfrich B; Zeng C; Baron A; Whitehead CM; Piazza G; Pamukcu R; Thompson WJ; Alila H; Nelson P; Bunn PA
Clin Cancer Res; 2002 Mar; 8(3):904-12. PubMed ID: 11895925
[TBL] [Abstract][Full Text] [Related]
2. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.
Whitehead CM; Earle KA; Fetter J; Xu S; Hartman T; Chan DC; Zhao TL; Piazza G; Klein-Szanto AJ; Pamukcu R; Alila H; Bunn PA; Thompson WJ
Mol Cancer Ther; 2003 May; 2(5):479-88. PubMed ID: 12748310
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
Bunn PA; Chan DC; Earle K; Zhao TL; Helfrich B; Kelly K; Piazza G; Whitehead CM; Pamukcu R; Thompson W; Alila H
Semin Oncol; 2002 Feb; 29(1 Suppl 4):87-94. PubMed ID: 11894018
[TBL] [Abstract][Full Text] [Related]
4. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Witta SE; Gustafson DL; Pierson AS; Menter A; Holden SN; Basche M; Persky M; O'Bryant CL; Zeng C; Baron A; Long ME; Gibbs A; Kelly K; Bunn PA; Chan DC; Pallansch P; Eckhardt SG
Clin Cancer Res; 2004 Nov; 10(21):7229-37. PubMed ID: 15534096
[TBL] [Abstract][Full Text] [Related]
5. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.
Drugs R D; 2004; 5(4):220-6. PubMed ID: 15230629
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
Jones SF; Kuhn JG; Greco FA; Raefsky EL; Hainsworth JD; Dickson NR; Thompson DS; Willcutt NT; White MB; Burris HA
Clin Lung Cancer; 2005 May; 6(6):361-6. PubMed ID: 15943897
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
Weiss GJ; Vokes EE; Bunn PA; Magree L; Rusk J; Albert D; Kelly K
J Thorac Oncol; 2007 Oct; 2(10):933-8. PubMed ID: 17909356
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel and exisulind in hormone-refractory prostate cancer.
Ryan CW; Stadler WM; Vogelzang NJ
Semin Oncol; 2001 Aug; 28(4 Suppl 15):56-61. PubMed ID: 11685730
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.
Soriano AF; Helfrich B; Chan DC; Heasley LE; Bunn PA; Chou TC
Cancer Res; 1999 Dec; 59(24):6178-84. PubMed ID: 10626810
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
Ryan CW; Stadler WM; Vogelzang NJ
BJU Int; 2005 May; 95(7):963-8. PubMed ID: 15839914
[TBL] [Abstract][Full Text] [Related]
11. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
Piazza GA; Thompson WJ; Pamukcu R; Alila HW; Whitehead CM; Liu L; Fetter JR; Gresh WE; Klein-Szanto AJ; Farnell DR; Eto I; Grubbs CJ
Cancer Res; 2001 May; 61(10):3961-8. PubMed ID: 11358813
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
13. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
[TBL] [Abstract][Full Text] [Related]
14. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.
Reddy BS; Kawamori T; Lubet RA; Steele VE; Kelloff GJ; Rao CV
Cancer Res; 1999 Jul; 59(14):3387-91. PubMed ID: 10416599
[TBL] [Abstract][Full Text] [Related]
15. Combined effect of docetaxel and cisplatin for non-small cell lung cancer cell lines in vitro.
Wang H
Nagoya J Med Sci; 2000 Nov; 63(3-4):129-37. PubMed ID: 11201987
[TBL] [Abstract][Full Text] [Related]
16. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Lu Z; Wientjes TS; Au JL
Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.
Garcia AA; Iqbal S; Quinn D; Edwards S; Lenz HJ; Weber J
Invest New Drugs; 2006 Jan; 24(1):79-83. PubMed ID: 16379039
[TBL] [Abstract][Full Text] [Related]
18. 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.
Fulzele SV; Chatterjee A; Shaik MS; Jackson T; Ichite N; Singh M
Anticancer Drugs; 2007 Jan; 18(1):65-78. PubMed ID: 17159504
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro.
Amorino GP; Hamilton VM; Choy H
Radiat Oncol Investig; 1999; 7(6):343-52. PubMed ID: 10644057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
